Progressive behavior

The early results of trials for two injectable, investigational antiretroviral therapies, VH4524184 and VH4011499, have the potential for extended dosing intervals.

Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.

In a real-world study, researchers found this data by comparing treatment patterns, healthcare resource utilization, and costs between patients receiving CAR T-cell therapy and those treated with the non-CAR T standard of care.

In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded those from the twice-yearly dosing.